Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

JPMorgan lowered the firm’s price target on BioNTech (BNTX) to $124 from $125 and keeps a Neutral rating on the shares. The firm updated ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

The firm updated estimates following Pfizer’s Comirnaty results and vaccine script trends for Comirnaty, Spikevax, and mResvia. Published first on TheFly – the ultimate source for real-time, ...

Unlike at the height of the pandemic, oral antiviral therapy Paxlovid is Pfizer's strongest COVID-19 product now instead of its Comirnaty vaccine. In the third quarter of 2024, Paxlovid raked in sales ...

Portfolio manager Dave Wagner stressed the need for further cost management and streamlined operations. With optimistic ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

Pfizer has been looking for a fresh start after a rocky 2023, when its stock dropped more than 40% as some of the company's guidance proved overly optimistic. Last October, the company unveiled a cost ...